![Priya Mande](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Priya Mande
Keine laufenden Positionen mehr
Ursprung des Netzwerks ersten Grades von Priya Mande
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Akamis Bio Ltd.
![]() Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.
6
| Holding Company | Biotechnology | 6 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Priya Mande
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
Goldman Sachs International
![]() Goldman Sachs International Investment Banks/BrokersFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Investment Banks/Brokers | Analyst-Equity | |
Advent Venture Partners LLP
![]() Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
Piramed Ltd.
![]() Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Miscellaneous Commercial Services | Chief Executive Officer | |
Anchorage Capital Group LLC
![]() Anchorage Capital Group LLC Investment ManagersFinance Anchorage Capital Group LLC is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Kevin Ulrich in 2003 as Anchorage Advisors LLC. They are a subsidiary of Anchorage Advisors Management LLC. Anchorage Capital Group provides investment advisory services to private investment funds and structured credit vehicles. | Investment Managers | Director/Board Member | |
TRILLIUM THERAPEUTICS | Biotechnology | Director/Board Member | |
Oxford BioTherapeutics Ltd.
![]() Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Artax Biopharma, Inc.
![]() Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
ROIVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member | |
University of Virginia | College/University | Undergraduate Degree | |
The Trustees of Columbia University in The City of New York | College/University | Masters Business Admin | |
Goldman Sachs & Co. LLC
![]() Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Investment Banks/Brokers | Analyst-Equity | |
Index Ventures SA
![]() Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Private Equity Analyst | |
Rutgers State University of New Jersey | College/University | Masters Business Admin | |
Lehigh University | College/University | Undergraduate Degree | |
The University of Nottingham | College/University | Doctorate Degree | |
University of Barcelona | College/University | Doctorate Degree | |
Escuela de Organización Industrial | College/University | Masters Business Admin | |
Aravis AG
![]() Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Investment Managers | Private Equity Investor | |
NanoDimension Management Ltd.
![]() NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | Investment Managers | Private Equity Investor | |
Touchstone Innovations Investment Management Ltd.
![]() Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Director/Board Member | |
Crescendo Biologics Ltd.
![]() Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Akinion Pharmaceuticals AB
![]() Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman | |
Phogen Ltd. | Chairman | ||
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
TopiVert Ltd.
![]() TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Advent Life Sciences LLP
![]() Advent Life Sciences LLP BiotechnologyHealth Technology Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry. | Biotechnology | Corporate Officer/Principal | |
IP Group Plc /Venture Capital/
![]() IP Group Plc /Venture Capital/ Investment ManagersFinance IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
Harvard Business School | College/University | Masters Business Admin | |
Minoryx Therapeutics SL
![]() Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member | |
Chronos Therapeutics Ltd.
![]() Chronos Therapeutics Ltd. BiotechnologyHealth Technology Chronos Therapeutics Ltd. manufactures drugs. It pursuing innovative therapeutics for age-related diseases through the joint efforts of experts in medical research, drug discovery and business development. The company was founded in 2009 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Chairman | |
WindMIL Therapeutics, Inc.
![]() WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | Medical Specialties | Corporate Officer/Principal | |
Mironid Ltd.
![]() Mironid Ltd. Pharmaceuticals: MajorHealth Technology Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Macrophage Pharma Ltd.
![]() Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | Biotechnology | Chairman | |
R-Pharm US LLC
![]() R-Pharm US LLC Pharmaceuticals: MajorHealth Technology R-Pharm US LLC engages in development and commercialization of medicines to treat cancer. Its products include IXEMPRA and episil. The company was founded by Mark Pavao and Demetrios Kydonieus in 2014 and is headquartered in Princeton, NJ. | Pharmaceuticals: Major | Director of Finance/CFO | |
GENERATION BIO CO. | Pharmaceuticals: Major | Director/Board Member | |
ORCHARD THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
CytoKi Pharma ApS
![]() CytoKi Pharma ApS Miscellaneous Commercial ServicesCommercial Services CytoKi Pharma ApS engages in the research and experimental development within biotechnology. It develops therapeutics for serious tissue and organ injuries. The company was founded by Rasmus Jørgensen on June 12, 2019 and is headquartered in Vaerlose, Denmark. | Miscellaneous Commercial Services | Director/Board Member | |
ZENTALIS PHARMACEUTICALS, INC. | Biotechnology | Director of Finance/CFO | |
KINNATE BIOPHARMA INC. | Pharmaceuticals: Major | Director/Board Member | |
Nautilus Subsidiary, Inc.
![]() Nautilus Subsidiary, Inc. Information Technology ServicesTechnology Services Nautilus Biotechnology, Inc. operates as a biopharmaceutical company. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in San Carlos, CA. | Information Technology Services | Director/Board Member | |
PAXMEDICA, INC. | Biotechnology | Director/Board Member | |
NAUTILUS BIOTECHNOLOGY, INC. | Biotechnology | Director/Board Member | |
The Andalusia Foundation | Director/Board Member | ||
Vandria SA
![]() Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
Vereinigte Staaten | 20 |
Vereinigtes Königreich | 19 |
Kanada | 4 |
Schweiz | 4 |
Spanien | 4 |
Sektoral
Health Technology | 25 |
Finance | 10 |
Consumer Services | 9 |
Commercial Services | 5 |
Technology Services | 2 |
Operativ
Director/Board Member | 36 |
Independent Dir/Board Member | 15 |
Director of Finance/CFO | 12 |
Chairman | 9 |
Corporate Officer/Principal | 7 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Charles Rowland | 25 |
Michael G. Moore | 16 |
Melissa Epperly | 13 |
Daniel Bach | 13 |
Karen LaRochelle | 10 |
Howard Davis | 2 |
- Börse
- Insiders
- Priya Mande
- Unternehmensverbindungen